Arena Pharmaceuticals, Inc.
Records under this name other than the patents Arena Pharmaceuticals, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 113 patents it holds.
Back to Arena Pharmaceuticals, Inc.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,780,827 | Substituted 3-Phenoxyazetidin-1-YL-PYRAZINES Formerly held In force · High confidence | In force | High confidence | |
| US 12,115,157 | 3-Phenoxyazetidin-1-YL-HETEROARYL Pyrrolidine Derivatives and the Use Thereof as Medicament Formerly held In force · High confidence | In force | High confidence | |
| US 8,802,845 | Processes for the Preparation of 8-Chloro-1-Methyl-2,3,4,5-Tetrahydro-1H-3-Benzazepine and Intermediates Related Thereto Lapsed on the fee record Ended Aug 12, 2026 · High confidence | Lapsed on the fee record | Ended Aug 12, 2026 | High confidence |
| US 8,754,238 | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of disorders related thereto Lapsed on the fee record Ended Jun 17, 2026 · USPTO record | Lapsed on the fee record | Ended Jun 17, 2026 | USPTO record |
| US 8,980,881 | Crystalline Forms of (R)-8-Chloro-1-Methyl-2,3,4,5-Tetrahydro-1H-3-Benzazepine Hydrochloride Term ended Ended no later than Apr 9, 2026 · Low confidence | Term ended | Ended no later than Apr 9, 2026 | Low confidence |
| US 9,867,822 | Cannabinoid receptor modulators Lapsed on the fee record Ended Jan 16, 2026 · USPTO record | Lapsed on the fee record | Ended Jan 16, 2026 | USPTO record |
| US 7,241,792 | Fused pyrazole derivatives and methods of treatment of metabolic-related disorders thereof Term ended Term ended Dec 29, 2025 · USPTO record | Term ended | Term ended Dec 29, 2025 | USPTO record |
| US 8,697,686 | Crystalline forms of (R)-8-chloro-1-methyl-2,3,4,5-thtrahydro-1H-3-benzazepine hydrochloride Term ended Ended no later than Dec 20, 2025 · USPTO record | Term ended | Ended no later than Dec 20, 2025 | USPTO record |
| US 7,884,101 | 3-Phenyl-PYRAZOLE Derivatives as Modulators of the 5-HT2A Serotonin Receptor Useful for the Treatment of Disorders Related Thereto Term ended Term ended Dec 8, 2025 · High confidence | Term ended | Term ended Dec 8, 2025 | High confidence |
| US 8,785,441 | 3-Phenyl-PYRAZOLE Derivatives as Modulators of the 5-HT2A Serotonin Receptor Useful for the Treatment of Disorders Related Thereto Term ended Term ended Nov 17, 2025 · High confidence | Term ended | Term ended Nov 17, 2025 | High confidence |